
6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma

September 26-29, 2018
Rotterdam, The Netherlands
Venue: De Doelen International Congress Centre

Presenting the latest scientific and clinical advances in childhood, adolescent and young adult Non-Hodgkin Lymphoma

Hosted By:
Mitchell S. Cairo, MD - Chair
Chief, Pediatric Hematology, Oncology and Stem Cell Transplantation
Professor of Pediatrics, Medicine, Pathology, Microbiology & Immunology and Cell Biology & Anatomy
Maria Fareri Children’s Hospital
Westchester Medical Center (WMC)
New York Medical College

Auke Beishuizen, MD, PhD, - Co-Chair
Pediatric Oncologist/Hematologist
Erasmus MC – Sophia Children’s Hospital
University Medical Center Rotterdam
And
Princess Máxima Center for Pediatric Oncology
Utrecht


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of New York Medical College and Pediatric Cancer Research Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

New York Medical College designates this Live activity for a maximum of 23.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
## SCHEDULE AT A GLANCE

<table>
<thead>
<tr>
<th></th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Registration</td>
<td>2:00 PM – 9:00 PM</td>
<td>7:00 AM – 5:00 PM</td>
<td>7:00 AM – 5:00 PM</td>
<td>7:00 AM – 1:00 PM</td>
</tr>
<tr>
<td><strong>NHL Wellness and</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Survivorship</strong></td>
<td>6:00 PM – 8:00 PM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chair:</td>
<td>Mitchell S. Cairo, MD, USA</td>
<td>Auke Beishuizen, MD, PhD, Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chair:</td>
<td>Auke Beishuizen, MD, PhD, Netherlands</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>International Scientific Committee &amp; Faculty:</strong></td>
<td>Oussama Abla, MD, Canada</td>
<td>Sarah Alexander, MD, Canada</td>
<td>Carl Allen, MD, PhD, USA</td>
<td>Mara Andres, MD, PhD, Spain</td>
</tr>
<tr>
<td></td>
<td>Mara Andres, MD, PhD, Spain</td>
<td>Sarah Alexander, MD, Canada</td>
<td>Carl Allen, MD, PhD, USA</td>
<td>Mara Andres, MD, PhD, Spain</td>
</tr>
<tr>
<td></td>
<td>Stephen M. Ansell, MD, PhD, USA</td>
<td>Andishe Attarbaschi, MD, Austria</td>
<td>Anthony N. Audino, MD, USA</td>
<td>Matthew Barth, MD, USA</td>
</tr>
<tr>
<td></td>
<td>Myriam Weyl Ben-Arush, MD, Israel</td>
<td>Catherine Bollard, MD, USA</td>
<td>Laurence Brugieres, MD, France</td>
<td>Ilia Bultoiarow, MD, USA</td>
</tr>
<tr>
<td></td>
<td>Laura Pasqualucci, MD, USA</td>
<td>Alina Fedorova, MD, Russia</td>
<td>Monika Csoka, MD, Hungary</td>
<td>Amos Burke, MD, UK</td>
</tr>
<tr>
<td></td>
<td>Alan Davidson, MD, South Africa</td>
<td>Guillermo Cantada, MD, PhD, Argentina</td>
<td>Birgit Burkhardt, MD, PhD, Germany</td>
<td>Irina Budalov, MD, Russia</td>
</tr>
<tr>
<td></td>
<td>Alan KS Chiang, MD, PhD, Hong Kong</td>
<td>Anna Corradi, MD, Germany</td>
<td>Alex Czarnecki, MD, USA</td>
<td>Lukas Kenner, MD, Austria</td>
</tr>
<tr>
<td></td>
<td>Christine Damm-Welk, PhD, Germany</td>
<td>Ronit Elhaish, MD, Israel</td>
<td>Alina Fedorova, MD, PhD, Russia</td>
<td>Wolfram Klapper, MD, Germany</td>
</tr>
<tr>
<td></td>
<td>Alan Davidson, MD, South Africa</td>
<td>Allyson Flower, MD, USA</td>
<td>J. Kimble Frazer, MD, PhD, USA</td>
<td>Claudette Esteves Klumb, MD, PhD, Brazil</td>
</tr>
<tr>
<td></td>
<td>Andishe Attarbaschi, MD, Austria</td>
<td>Paul Galarady, MD, USA</td>
<td>Stanton Goldman, MD, USA</td>
<td>Ryoji Kobayashi, MD, PhD, Japan</td>
</tr>
<tr>
<td></td>
<td>Anthony N. Audino, MD, USA</td>
<td>Thomas Gross, MD, PhD, USA</td>
<td>Michelle Hermiston, MD, PhD, USA</td>
<td>Yukhi Koga, MD, PhD, Japan</td>
</tr>
<tr>
<td></td>
<td>Matthew Barth, MD, USA</td>
<td>Thomas Gross, MD, PhD, USA</td>
<td>Jessica Hochberg, MD, USA</td>
<td>Tetsuya Mori, MD, PhD, Japan</td>
</tr>
<tr>
<td></td>
<td>Myriam Weyl Ben-Arush, MD, Israel</td>
<td>Scott Howard, MD, USA</td>
<td>Scott Howard, MD, USA</td>
<td>Lara MussoLin, PhD, Italy</td>
</tr>
<tr>
<td></td>
<td>Laura Pasqualucci, MD, USA</td>
<td>Ling Jin, MD, China</td>
<td>Ling Jin, MD, China</td>
<td>Ryotaro Nakamura, MD, USA</td>
</tr>
<tr>
<td></td>
<td>Alina Fedorova, MD, Russia</td>
<td>Lukas Kenner, MD, Austria</td>
<td>Lukas Kenner, MD, Austria</td>
<td>Veronique Minard-Colin, MD, PhD, France</td>
</tr>
<tr>
<td></td>
<td>Guillermo Cantada, MD, PhD, Argentina</td>
<td>Wolfram Klapper, MD, Germany</td>
<td>Wolfram Klapper, MD, Germany</td>
<td>Tetsuya Mori, MD, PhD, Japan</td>
</tr>
<tr>
<td></td>
<td>Anna Corradi, MD, Germany</td>
<td>Claudette Esteves Klumb, MD, PhD, Brazil</td>
<td>Claudette Esteves Klumb, MD, PhD, Brazil</td>
<td>Tetsuya Mori, MD, PhD, Japan</td>
</tr>
<tr>
<td></td>
<td>Anna Corradi, MD, Germany</td>
<td>Ronit Elhaish, MD, Israel</td>
<td>Ryoji Kobayashi, MD, PhD, Japan</td>
<td>Lara MussoLin, PhD, Italy</td>
</tr>
<tr>
<td></td>
<td>Anna Corradi, MD, Germany</td>
<td>Allyson Flower, MD, USA</td>
<td>Paul Galarady, MD, USA</td>
<td>Ryotaro Nakamura, MD, USA</td>
</tr>
<tr>
<td></td>
<td>Anna Corradi, MD, Germany</td>
<td>J. Kimble Frazer, MD, PhD, USA</td>
<td>Stanton Goldman, MD, USA</td>
<td>Laura Pasqualucci, MD, USA</td>
</tr>
<tr>
<td><strong>Opening Ceremony</strong></td>
<td>8:00 AM – 8:15 AM</td>
<td>Angelo Rosolen, MD</td>
<td>Plenary Session I</td>
<td>Plenary Session I</td>
</tr>
<tr>
<td><strong>Plenary Session I</strong></td>
<td>B-Cell NHL</td>
<td>9:00 AM – 10:45 AM</td>
<td>9:00 AM – 10:45 AM</td>
<td>8:00 AM – 10:00 AM</td>
</tr>
<tr>
<td><strong>Break</strong></td>
<td>10:45 AM – 11:00 AM</td>
<td></td>
<td>10:45 AM – 11:00 AM</td>
<td>10:00 AM – 10:15 AM</td>
</tr>
<tr>
<td><strong>Lunch</strong></td>
<td>12:45 – 1:45 PM</td>
<td></td>
<td>12:45 – 1:45 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session II</strong></td>
<td>Adolescent and Young Adult NHL &amp; HL</td>
<td>11:00 AM – 12:40 PM</td>
<td>11:00 AM – 12:40 PM</td>
<td>10:15 – 11:45 PM</td>
</tr>
<tr>
<td><strong>Break</strong></td>
<td>3:45 PM – 4:00 PM</td>
<td></td>
<td>3:45 PM – 4:00 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Lunch</strong></td>
<td>12:45 – 1:45 PM</td>
<td></td>
<td>12:45 – 1:45 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session III</strong></td>
<td>Lymphoma Translational Biology (Dedicated in memory of Warren Sanger, PhD)</td>
<td>1:45 PM – 3:45 PM</td>
<td>1:45 PM – 3:45 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Break</strong></td>
<td>3:15 PM – 3:30 PM</td>
<td></td>
<td>3:15 PM – 3:30 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session IV</strong></td>
<td>Lymphoma Immunology, BMT and Cell Therapy</td>
<td>4:00 PM – 5:45 PM</td>
<td>4:00 PM – 5:45 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Welcome Reception</strong></td>
<td>6:00 PM – 7:30 PM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**International Scientific Committee & Faculty:** (Continued)

- Catherine Patte, MD, France
- Sherrie Perkins, MD, PhD, USA
- Rob Pieters, MD, Netherlands
- Marta Pillon, MD, Italy
- Leticia Quintanilla-Fend, MD, Germany
- Alfred Reiter, MD, Germany
- Stanley Riddell, MD, USA
- Leslie Robison, PhD, USA
- Lisa Giulino-Roth, MD, USA
- Elena V. Samochatova, MD, PhD, Russia
- John T. Sandlund, MD, USA
- Jennifer Sanmann, PhD, USA
- Florian Scherer, MD, USA
- Margaret Shipp, MD, USA
- Bruce Shiramizu, MD, USA
- Reiner Siebert, MD, Germany
- Filippo Sprefico, MD, Italy
- Jaroslav Sterba MD, PhD, Czech Republic
- Jan Styczynski, MD, Poland
- X. F. Sun, MD, China
- Ritsuro Suzuki, MD, PhD, Japan
- Amanda Termuhlen, MD, USA
- Suzanne Turner, PhD, UK
- Anne Uyttebroeck, MD, PhD, Belgium
- Timur T. Vailiev, MD, PhD, Russia
- Rein Willemze, MD, Netherlands
- Birte Wistinghausen, MD, USA
- Wilhelm Woessmann, MD, Germany
- Ana Xavier, MD, USA
- Jing Yang, MD, China
- Yonghong Zhang, MD, China
- Jozsef Zsiros, MD, Netherlands
- Christian Michel Zwaan, MD, PhD, Netherlands
Wednesday, September 26, 2018

2:00 – 9:00 PM  REGISTRATION

6:00 – 8:00 PM  Pre-Congress Workshop
Childhood and Adolescent NHL Wellness and Survivorship
Jessica Hochberg, MD, USA & Leslie Robison, PhD, USA

6:00 – 6:30 PM  CHILDHOOD AND ADOLESCENT NHL SURVIVORSHIP: THE CCSS PERSPECTIVE
Leslie Robison, PhD, USA

6:30 – 6:45 PM  CHILDHOOD AND ADOLESCENT NHL SURVIVORSHIP: THE BFM PERSPECTIVE
Birgit Burkhardt, MD, PhD, Germany & Wilhelm Woessmann, MD, Germany

6:45 – 7:00 PM  Burkitt Lymphoma (BL): Effect of Cyclophosphamide (CPM) on the Menarche and Fertility Rate in 113 Cameroonian patients.
Peter B Hesseling¹, Glenn Afunchwi ², Vera Njamshi³, Comfort Kimbi⁴, Patience Nfor⁵, Bernard Njodzeka⁶, Paul Wharin⁷, Francine Kouya⁸, Heather R Draper ⁹
¹Department of Paediatrics and Child Health, Tygerberg Children’s Hospital, University of Stellenbosch, South Africa, ²Banso Baptist Hospital, Northwest Region, Cameroon, ³Banso Baptist Hospital, Northwest Region, Cameroon, ⁴Mbingo Baptist Hospital, Northwest region, Cameroon, ⁵Mutengene Baptist Hospital, Southwest Region, Cameroon, ⁶Mutengene Baptist Hospital, Southwest Region, Cameroon, ⁷Beryl Thyer Memorial Africa Trust, Kettering, UK, ⁸Mbingo Baptist Hospital, Northwest Region, Cameroon; Heather R Draper MSc – ⁹Desmond Tutu TB Centre, Department of Paediatrics, University of Stellenbosch, South Africa

7:00 – 7:15 PM  Influence of Methylenetetrahydrofolate Reductase Gene Polymorphisms on the High-dose Methotrexate Related Toxicity in Children Cancer Patients
Suying Lu, MD¹,²,³, Xiaofei Sun, MD¹,²,³*, Zijun Zhen, MD, PhD¹,²,³, Jia Zhu, MD, PhD¹,²,³, Juan Wang, MD¹,²,³, Feifei Sun, MD, PhD¹,²,³, Junting Huang, MD, PhD¹,²,³.
¹State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China; ²Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China; ³Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China

7:15 – 7:30 PM  Long Term Follow Up of Pediatric Lymphoma Survivors upon Entry into a Wellness and Survivorship Program
Jessica Hochberg, MD¹; Tara Giblin, PNP¹; Suzanne Braniecki, PhD¹, Rose Bartone, LCSW¹, Lauren Harrison, RN, MSN¹, Jackie Basso, RN, MSN, PNP¹, Allyson Flower, MD¹ and Mitchell Cairo, MD¹,²,³,⁴,⁵
¹Pediatrics, New York Medical College, Valhalla, NY; ²Medicine, ³Pathology, ⁴Microbiology and Immunology and ⁵Cell Biology and Anatomy, New York Medical College, Valhalla, NY

7:30 – 8:00 PM  Panel Discussion – Drs. Hochberg, Robison, Burkhardt and Audience Participation
Thursday, September 27, 2018

7:00 AM - 5:00 PM  REGISTRATION

8:00 – 8:10 AM  OPENING CEREMONY
Mitchell S. Cairo, MD, Chair, USA

8:10 – 8:15 AM  Auke Beishuizen, MD, PhD, Co-Chair, Netherlands

8:15 – 9:00 AM  ANGELO ROSOLEN, MD, MEMORIAL LECTURE

8:15 – 8:20 AM  INTRODUCTION
Marta Pillon, MD, Italy, and Lara Mussolin, PhD, Italy - Co-Chairs

8:20 – 9:00 AM  PEDIATRIC NON-HODGKIN LYMPHOMA REVISITED WITH A VIEW FROM THE DISTANCE
Alfred Reiter, MD, Germany

9:00 – 10:45 AM  PLENARY SESSION I - B-CELL NON-HODGKIN LYMPHOMA
Moderators - Stanton Goldman, MD, USA & Sarah Alexander, MD, Canada

9:00 – 9:20 AM  PROMISING TARGETS IN B-CELL PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Margaret Shipp, MD, USA

9:20 – 9:40 AM  DNA METHYLOME IN BURKITT LYMPHOMA
Reiner Siebert, MD, Germany

9:40 – 10:00 AM  DIAGNOSIS AND TREATMENT OF RARE B-NHL VARIANTS IN CHILDREN AND ADOLESCENTS
Andishe Attarbaschi, MD, Austria

10:00 – 10:10 AM  Reduced Burden of Oncologic Therapy in Children, Adolescents and Young Adults with Good Risk (GR) CD20+ Mature B-Cell Lymphoma
**Stan Goldman, MD**¹, Matthew Barth, MD², Jessica Hochberg, MD³, Liana Klejmont, Pharm D³, Lauren Harrison, RN, MSN³, Quih Shi, PhD³, Javier Oesterheld, MD⁶, Kenneth Heym, MD⁷, Sherrie Perkins, MD, PhD⁶, Rodney Miles, MD, PhD⁶, Bruce Shiramizu, MD⁷, and Mitchell Cairo, MD³,⁸,⁹,¹⁰,¹¹,¹²

¹Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX; Departments of ²Pediatrics, Roswell Park Cancer Institute, Buffalo, NY; ³Pediatrics, ⁴Medicine, ⁵Pathology, ⁶Microbiology & Immunology, ⁷Cell Biology & Anatomy, ⁸Biostatistics, New York Medical College, Valhalla, NY; ⁹Levine Children’s Hospital, Charlotte, NC; ¹⁰Cook Children's Medical Center, ¹¹Pathology, University of Utah Health, Salt Lake City, UT; ¹²Tropical Medicine, Medical Microbiology & Pharmacology, University of Hawaii, Honolulu, HI.

10:10 – 10:20 AM  Cancer Stem Cells in Paediatric B-Cell Non-Hodgkin Lymphoma are Detectable by Side Population Analysis and May Contribute to Therapy Resistance
Sorcha Forde¹, Nina Prokoph¹, Liam C. Lee¹, Simon Bomken², G.A. Amos Burke³*, and Suzanne D. Turner¹*

*Corresponding author.
10:20 – 10:30 AM  **UCH-L1 Bypasses mTOR to Promote Protein Biosynthesis and is Required for MYC Driven Lymphomagenesis in Mice**
Sajjad Hussain¹, Tibor Bedekovics¹, Qiuling Liu², Wenqian Hu², Sarah H. Johnson³, George Vasmatzis³,⁴, Danielle G. May⁵, Kyle J. Roux⁵,⁶, and Paul J. Galardy¹,²,⁷
¹Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA; ²Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, 55905; ³Center for Individualized Medicine-Biomarker Discover, Mayo Clinic, Rochester, MN, 55905; ⁴Department of Molecular Medicine, Mayo Clinic, Rochester, MN, 55905; ⁵Enabling Technology Group, Sanford Research, Sioux Falls, SD 57104, USA; ⁶Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA; ⁷Division of Pediatric Hematology-Oncology, Mayo Clinic, Rochester, MN 55905, USA

10:30 – 10:45 AM  **Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers**

10:45 – 11:00 AM  **COFFEE BREAK**

11:00 – 12:40 PM  **PLENARY SESSION II - ADOLESCENT AND YOUNG ADULT NON-HODGKIN AND HODGKIN LYMPHOMA**
**Moderators** - Jessica Hochberg, MD, USA & Christine Mauz-Körholz, MD, Germany

11:00 – 11:20 AM  **PD-1 TARGETED THERAPY IN LYMPHOMAS**
Steve Ansell, MD, PhD, USA

11:20 – 11:40 AM  **EPIDEMIOLOGY AND OUTCOME OF AYA WITH NHL AND HODGKIN LYMPHOMA**
Allyson Flower, MD, USA

11:40 – 12:00 PM  **NOVEL TARGETED IMMUNOTHERAPY IN NEWLY DIAGNOSED CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA**
Jessica Hochberg, MD, USA

12:00 – 12:10 PM  **Nonbiological Factors Affecting Outcomes in Adolescent and Young Adults with Lymphoma.**
Ana C. Xavier¹, Luciano J. Costa²
¹Division of Hematology/Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States; ²Division of Hematology and Medical Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.

12:10 – 12:20 PM  **Clinical Features and Treatment Outcome of Children with Primary Mediastinal Large B-Cell Lymphoma in Taiwan**
Shih-Hsiang Chen¹, Chao-Ping Yang¹, on behalf of the Taiwan Pediatric Oncology Group (TPOG)
12:20 – 12:40 PM  Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

12:40 - 1:45 PM  LUNCH

1:45 – 3:45 PM  PLENARY SESSION III - LYMPHOMA TRANSLATIONAL BIOLOGY (DEDICATED IN MEMORY OF WARREN SANGER, PHD)

Moderators - Paul Galardy, MD, USA & Elizabeth Macintyre, MD, PhD, France

1:45 – 1:50 PM  INTRODUCTION
Jennifer N. Sanmann, PhD, USA

1:50 – 2:05 AM  THE T/MEYOILD INTERFACE IN IMMATURE T LYMPHOID MALIGNANCIES"
Elizabeth Macintyre, MD, PhD, France

2:05 – 2:25 PM  CIRCULATING TUMOR DNA (CTDNA) IN B-CELL LYMPHOMA
Florian Scherer, MD, USA

2:25 – 2:45 PM  THE ROLE OF LIQUID BIOPSY IN NON-HODGKIN LYMPHOMAS OF CHILDHOOD
Lara Mussolin, PhD, Italy

2:45 – 3:05 PM  MUTATIONAL LANDSCAPE OF PEDIATRIC-TYPE FOLLICULAR LYMPHOMA
Leticia Quintanilla-Fend, MD, Germany

3:05 – 3:15 PM  Discovery of the First Zebrafish B Cell Lymphoblastic Lymphoma Model
Chiara Borga PhD1, Gilseung Park1, Clay Foster PhD1, Jessica Burroughs-Garcia PhD1, Ameera Hasan MBBS1, Rikin Shah MD1, Megan Malone-Perez1, Teresa Scordino MD2, Rodney R. Miles MD, PhD3, James L. Regens PhD4, Geertruy te Kronnie PhD5, J. Kimble Frazer MD, PhD1

1Pediatric Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Pathology, University of Utah, and ARUP Institute for Clinical & Experimental Pathology, Salt Lake City, UT, 4Center for Intelligence and National Security, University of Oklahoma, Norman, OK, 5Department of Women’s and Children’s Health, University of Padua, Padua, Italy

3:15 – 3:25 PM  IG-MYC-Positive Leukemia and Lymphoma with Precursor B-Cell Phenotype are Genetically and Epigenetically Distinct from Burkitt Lymphomas
Cristina López1,2, Rabea Wagener1,2, Kortine Kleinheinz3,4, Julia Bausinger1, Sietse M. Aukema2, Inga Nage3, Umut H. Toprak3,4, Julian Seufert3,4, Janine Altmüller7, Holger Thiele8, Christof Schneider9, Julia Kolarova1,2, Jeongbin Park3,10, Daniel Hübschmann3,4, Eva M. Murga Penas2, Hans G. Drexler11, Andishe Attarbaschi12, Randi Hovland13, Eigil Kjeldsen14, Michael Kneba15, Udo Kontny16, Laurence de Leval17, Peter Nürnberg18, Ilske Oschlies18, David Oscier19, Brigitte Schlegelberger20, Stephan Stilgenbauer9, Wilhelm Wössmann21, Matthias Schlesner6, Birgit Burkhardt22, Wolfram Klapper18, Elaine S. Jaffe23, Ralf Küppers24, Reiner Siebert1,2,*
1Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany, 2Institute of Human Genetics, Christian-Albrechts University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany, 3German Cancer Research Center (DKFZ), Division of Theoretical Bioinformatics, Heidelberg, Germany, 4Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg, Germany, 5Institute of Pharmacology, Christian-Albrechts University Kiel, Germany, 6German Cancer Research Center (DKFZ), Bioinformatics and Omics Data Analytics, Heidelberg, Germany, 7Cologne Center for Genomics, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany, 8Cologne Center for Genomics, University of Cologne, Cologne, Germany, 9Department of Internal Medicine III, University of Ulm, Ulm, Germany, 10Faculty of Biosciences, Heidelberg University, Heidelberg, Germany, 11Leibniz-Institute DSMZ- German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany, 12Department of Pediatric Hematology and Oncology, St Anna Children’s Hospital, Medical University of Vienna, Austria, 13Department for Medical Genetics, Haukeland University Hospital, Bergen, Norway, 14Cancercytogenetics Section, Hemodiagnostic Laboratory, Department of Haematology, Cancer and Inflammation Center, Aarhus University Hospital, Aarhus C, Denmark, 15Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany, 16Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany, 1 Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland, 18Hematopathology Section, Christian-Albrechts-University, Kiel, Germany, 19Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, UK, 20Department of Human Genetics, Hannover Medical School, Hannover, Germany, 21Department of Pediatric Hematology and Oncology, Justus-Liebig University, Gießen, and NHL-BFM Study Center, Germany, 22Department of Pediatric Hematology and Oncology and NHL-BFM study center, University Hospital Münster, Münster, Germany, 23Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, USA, 24Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Medical School, Essen, Germany. 3shared first authorship

3:25 – 3:35 PM
Mutational Spectrum of Relapse in Pediatric and Adolescent Patients with T-LBL

Tasneem Khanam1, Charlotte Rüther1, Christoph Bartenhagen2,5, Jochen Seggewiß3, Heidi Herbrüggen1, Stephanie Müller1, Christian Wünsch2, Ilse Oschlies4, Wolfram Klapper4, Martin Dugas5, Sarah Sandmann5, Birgit Burkhardt1

1Paediatric Hematology and Oncology, University Hospital Muenster, Germany, 2Institute of Medical Informatics, Muenster University, 3Institute of Human genetics, Muenster University, 4Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany, 5Department of Experimental Pediatric Oncology, University of Cologne

3:35 – 3:50PM
Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

3:50 – 4:00 PM
COFFEE BREAK

4:00 – 5:45 PM
PLENARY SESSION IV - LYMPHOMA IMMUNOLOGY, BMT AND CELL THERAPY

Moderators – Wilhelm Woessmann, MD, Germany & Mitchell S. Cairo, MD, USA
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY NHL
Wilhelm Woessmann, MD, Germany

NEW ADVANCES ON CAR-T-CELL THERAPY IN B-NHL
Stanley Riddell, MD, USA

CMV-CD19 BI-SPECIFIC CAR T CELLS AND POST-INFUSION CMV VACCINE STRATEGIES
Ryotaro Nakamura, MD, USA

Safety and Efficacy of Myeloablative Conditioning Autologous Stem Cell Transplantation, Targeted Immunotherapy, and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Children, Adolescents, and Young Adults with Relapsed/Refractory Mature B-Cell Non Hodgkin Lymphoma
Aliza Gardenswartz, MD1, B Mehta, MD1, N El-Mallawany, MD1, C van de Ven, MS1, J Hochberg, MD1, A Flower, MD1, E Morris, RN, BSN1, L Harrison, RN, MSN1, J Basso, RN, MSN, CPNP1, P Gerard2, J Ayello, MS1, L A Baxter-Lowe, PhD3, M S Cairo, MD1,4,5,6,7.
1Dept of Pediatrics, New York Medical College, Valhalla, NY; 2 Dept of Radiology, New York Medical College, Valhalla, NY; 3Dept of Pathology, Children’s Hospital Los Angeles, CA; 4Dept of Medicine, New York Medical College, Valhalla, NY; 5 Dept of Pathology, New York Medical College, Valhalla, NY; 6 Dept of Microbiology and Immunology, and 7 Dept of Cell Biology and Anatomy, New York Medical College, Valhalla, NY

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells
Julie Rivers1, Colleen Annesley1, Corinne Summers1, Olivia Finney2, Michael Pulsipher3, Alan Wayne3, Julie Park4, Michael Jensen2, Rebecca Gardner1
1Seattle Children’s Hospital, Seattle, WA, USA; 2Seattle Children’s Research Institute, Seattle, WA, USA; 3Children’s Hospital of Los Angeles, Los Angeles, CA, USA

Role of HSCT in Children and Adolescents with Refractory or Relapsed NHL
Birgit Burkhardt1, Marta Pillon2, Mary Taj3, Nathalie Garnier4, Veronique Minard5, Volkan Hazar6, Karin Mellgren7, Tomoo Osumi8, Alina Fedorova9, Natalia Myakova10, Jaime Verdu-Amoros11, Mara Andres12, Edita Kabickova13, Andishe Attarbaschi14, Alan Chiang15, Eva Bubanska16, Svetlana Donska17, Lisa Lyngsie Hjalgrim18, Jacek Wachowiak19, Anna Pieczonka19, Anne Uyttebroeck20, Jan Loeffen21, Jochen Buechner22, Felix Niggli23, Julia Palma24, Amos Burke25, Auke Beishuizen21, Kristin Koeppen1, Heidi Herbrueggen1, Wilhelm Woessmann26, Martin Zimmermann27, Adriana Balduzzi28
1University Hospital Muenster, Department of Pediatric Hematology, Oncology and BMT, Münster, Germany; 2University-Hospital of Padua, Department of Child and Woman Health, Oncology Hematology Division, Padua, Italy; 3Royal Marsden Hospital, Department of Paediatric Oncology, Surrey, United Kingdom; 4Hospices Civils de Lyon, Institute of Pediatric Hematology and Oncology, Lyon cedex, France; 5Gustave Roussy Cancer Campus, Department of Pediatric Oncology, Villejuif, France; 6Medical Park Göztepe Hospital, Departments of Pediatric Hematology and Oncology and BMT Unit, Istanbul, Turkey; 7Sahlgrensk University Hospital, Department of Pediatric Oncology and Hematology, The Queen Silvia Children’s Hospital, Gothenburg, Sweden; 8Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan; 9Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Clinical Research Department, Minsk, Belarus; 10Pediatric Hematology and Oncology,
Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, University Hospital Valencia, Department of Pediatric Hematology and Oncology, Valencia, Spain, University Hospital Le Fe, Department of Pediatric Oncology, Valencia, Spain, Charles University & University Hospital Motol, Department of Paediatric Haematology and Oncology, Prague, Czech Republic, St. Anna Children's Hospital, Medical University of Vienna, Department of Pediatric Hematology and Oncology, Vienna, Austria, Department of Pediatrics & Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Slovak Health University and Children's Faculty Hospital, Clinic of Pediatric Oncology and Hematology, Banská Bystrica, Slovakia, National Ukrainian Children's Hospital “Ochmatdyt”, Center of Pediatric Oncohematology and BMT, Kiev, Ukraine, Department of Paediatrics and Adolescent Medicine, Copenhagen, Denmark, Poznan University of Medical Sciences, Department of Pediatric Oncology, Hematology and Transplantology, Poznan, Poland, University Hospital Gasthuisberg, Department of Paediatric Haematology and Oncology, Leuven, Belgium, Erasmus Medical Center Rotterdam, Sophia Children's Hospital, Department of Pediatric Oncology and Hematology, Rotterdam, The Netherlands, Oslo University Hospital, Department of Pediatric Hematology and Oncology, Oslo, Norway, University Children’s Hospital Zurich, Department of Pediatric Oncology, Zürich, Switzerland, University of Chile – Faculty of Medicine, Hospital Luis Calvo Mackenna, Department of Pediatrics – Bone Marrow Transplantation Unit, Santiago, Chile, Cambridge University Hospitals NHS Foundation Trust, Department of Paediatric Haematology and Oncology and Palliative Care, Addenbrooke’s Hospital, Cambridge, United Kingdom, Justus-Liebig-University, Department of Pediatric Hematology and Oncology, Giessen, Germany, Hannover Medical School, Department of Pediatric Hematology and Oncology, Hannover, Germany, Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 – 5:45 PM</td>
<td>Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question &amp; Answers</td>
</tr>
<tr>
<td>6:00 – 7:30 PM</td>
<td>WELCOME RECEPTION (ALL REGISTRANTS/FACULTY/STAFF/SIGNIFICANT OTHERS)</td>
</tr>
<tr>
<td></td>
<td>LOCATION: ROTTERDAM CITY HALL</td>
</tr>
</tbody>
</table>

**Friday, September 28, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM - 5:00 PM</td>
<td>REGISTRATION</td>
</tr>
<tr>
<td>7:30 – 8:30 AM</td>
<td>Meet the Professors (Choose One Session)</td>
</tr>
<tr>
<td>Session 1</td>
<td>MOLECULAR GENETICS IN NON-HODGKIN LYMPHOMA FOR THE CLINICIAN</td>
</tr>
<tr>
<td></td>
<td>Wolfram Klapper, MD, Germany</td>
</tr>
<tr>
<td>Session 2</td>
<td>DIAGNOSIS AND TREATMENT OF MATURE B-CELL LYMPHOMA IN CHILDREN:</td>
</tr>
<tr>
<td></td>
<td>CHALLENGING CASES</td>
</tr>
<tr>
<td></td>
<td>Catherine Patte, MD, France</td>
</tr>
</tbody>
</table>
Session 3  NEW PEDIATRIC INTERNATIONAL STAGING AND RESPONSE CRITERIA FOR CHILDHOOD AND ADOLESCENT NHL
John Sandlund, MD, USA

Session 4  HISTIOCYTOSIS SYNDROMES: NEW DIRECTIONS AND CHALLENGING CASES
Carl Allen, MD, PhD, USA

Session 5  NEW PATHOLOGICAL ENTITIES IN NHL: THE REVISED WHO CLASSIFICATION
Sherrie Perkins, MD, PhD, USA

8:30 – 10:15 AM  PLENARY SESSION V - ANAPLASTIC LARGE CELL LYMPHOMA
Moderators - Eric Lowe, MD, USA & Suzanne Turner, PhD, UK

8:30 – 8:50 AM  PRIMARY CUTANEOUS ALCL AND OTHER CUTANEOUS LYMPHOMAS IN CHILDREN AND ADOLESCENTS
Rein Willemze, MD, Netherlands

8:50 – 9:10 AM  NOVEL PATHWAYS OF ONCOGENESIS IN ALCL
Megan Lim, MD, PhD, USA

9:10 – 9:30 AM  ORIGINS AND PATHOGENESIS IN ALCL
Suzanne Turner, PhD, UK

9:30 – 9:40 AM  Comprehensive Characterization of Plasma-Derived Exosomes in Anaplastic Large Cell Lymphoma of Childhood
Federica Lovisa1,2, Enrico Gaffo1, Stefania Bortoluzzi3, Anna Garbin1,2, Piero Di Battista1,2, Elisa Carraro1, Piero Faruggia4, Alessandra Sala5, Matilde Piglione6, Luciana Vinti7, Emanuele S.G. D’Amore8, Giuseppe Basso1,2, Marta Pillon1, Lara Mussolin1,2  
1Clinic of Paediatric Onco-Haematology, Department of Women’s and Children’s Health, University of Padova, 2Istituto di Ricerca Pediatrica Città della Speranza, Padova, 3Department of Molecular Medicine, University of Padova, Padova, 4A.R.N.A.S. Ospedali Civico Di Cristina e Benfratelli, Palermo, 5Department of Paediatrics, San Gerardo Hospital, University of Milano-Bicocca, Fondazione MBBM, Monza, 6Department of Paediatric Onco-Haematology, Children’s Hospital Regina Margherita, Torino, 7Department of Paediatric Onco-Haematology, IRCCS Ospedale Bambino Gesù, Roma, 8Department of Pathological Anatomy, San Bortolo Hospital, Vicenza, Italy

9:40 – 9:50 AM  Examining the Function of PDGFRB in Anaplastic Large Cell Lymphoma
Ines Garces de los Fayos Alonso1,2,3, Michael Kothmayer2,3, Michaela Schlederer2, Oliver Pusch2, Simone Tangermann2, Sabine Lagger3 and Lukas Kenner1,2,3  
1Ludwig Boltzmann Institute for Cancer Research (LBI-CR), 1090 Vienna, 2Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, 3Unit of Laboratory Animal Pathology, Veterinary University of Vienna, 1210 Vienna, Center for Anatomy and Cell Biology, Medical University of Vienna, 1090 Vienna, Austria

9:50 – 10:00 AM  The Anaplastic Large Cell Lymphoma (ALCL)-Associated Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK) Directs Expression of the Nuclear Protein Brahma Related Gene 1 (BRG1) Driving Cell Survival
Stephen P. Ducray1,6, Gavin D. Garland1, Tu Truong1, Nina Prokoph1,6, Kojo S. J.
Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

COFFEE BREAK

PLENARY SESSION VI - T AND NK NON-HODGKIN LYMPHOMA
Moderators - Ana Xavier, MD, USA & Ritsuro Suzuki, MD, PhD, Japan

DIAGNOSIS AND OUTCOME OF EXTRANODAL NK/T-CELL LYMPHOMA IN CHILDREN AND ADOLESCENTS: THE JAPAN EXPERIENCE
Ritsuro Suzuki, MD, PhD, Japan

NOVEL TREATMENT AND OUTCOME OF EXTRANODAL NK AND T-CELL LYMPHOMA: THE BEIJING EXPERIENCE
Jing Yang, MD, China

AUTOLOGOUS VS. ALLOGENEIC HSCT FOR PATIENTS WITH T-CELL AND NK NON-HODGKIN LYMPHOMA
Amanda Termuhlen, MD, USA

Hydroa Vacciniforme-Like Lymphoproliferative Disorder: A Systematic Review
Ligia Ríos López, M.D.,1 Liliana Vasquez, M.D.,1 Iván Maza, M.D.,1; Brady Beltrán, M.D.,2, María Quiñonez, M.D.,3
1Pediatric Oncology Division, Rebagliati Hospital; Lima, 2Clinical Oncology Department, Rebagliati Hospital; Lima, 3Pathology Department, Rebagliati Hospital; Lima, Peru.

Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL)-Rare Non-Hodgkin Lymphoma in Children with Heterogenous Clinical Course. Polish Centres Experience
Lucyna Maciejka-Kemblowska1, Marta Kozłowska1, Jadwiga Maldyk2, Marcelina Osak1, Grażyna Wrobel3, Anna Wakulinska4, Tomasz Ociepa5, Andrzej Koltan6, Ewa Dukliewicz7, Ninela Irga-Jaworska1, Bernarda Kazanowska3, Elżbieta Adamkiewicz-Drozyńska1
1Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, 2Department of Developmental Pathology, Medical University of Warsaw, 3Department of Clinic of Pediatric Oncology, Hematology and Bone Marrow Transplantation, Wroclaw Medical University, 4Department of Pediatric Oncology, The Children’s Memorial Health Institute, Warsaw, 5Department of Pediatrics, Hematology and Oncology, Pomorski Medical University in Szczecin, 6Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University, Collegium Medicum Bydgoszcz, 7Clinic of Pediatric Hematology and Oncology, Medical University of Lublin, Poland.
Successful Outcome with Reduced-Intensity Condition Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Anaplastic Large-Cell Lymphoma

Reiji Fukano1,2, Naoto Fujita3, Tetsuya Mori4, Ryoji Kobayashi5, Tetsuo Mitsui6, Koji Kato7, Ritsuro Suzuki8, Junji Suzumiya8, Takahiro Fukuda9, Motohiro Shindo10, Nobuo Maseki11, Tatsu Shimoyama12, Keiko Okada13, Masami Inoue14, Jiro Inagaki1, Yoshiko Hashii15, Atsushi Sato16, Ken Tabuchi17

1Department of Pediatrics, National Kyushu Cancer Center, 2Department of Pediatrics, Yamaguchi University Graduate School of Medicine, 3Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, 4Department of pediatrics, St. Marianna University School of Medicine, 5Department of Pediatrics, Sapporo Hokuyu Hospital, 6Department of Pediatrics, Yamagata University Hospital, 7Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 8Department of Oncology/Hematology, Shimane University Hospital, 9Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 10Division of Gastroenterology and Hematology/Oncology Department of Medicine, Asahikawa Medical University, 11Department of Hematology, Saitama Cancer Center, 12Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, 13Department of Pediatric Hematology/Oncology, Osaka City General Hospital, 14Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, 15Department of Pediatrics, Osaka University Graduate School of Medicine; 16Hematology and Oncology, Miyagi Children’s Hospital, 17Division of Pediatrics, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital

Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

LUNCH

PLENARY SESSION VII - NOVEL THERAPEUTICS

Moderators - Veronique Minard-Colin, MD, PhD, France & Matthew Barth, MD, USA

NEW TARGETED THERAPY IN NHL
Mitchell S. Cairo, MD, USA

NOVEL TARGETS AND OUTCOME IN ALCL
Eric Lowe, MD, USA

NOVEL AGENTS IN DEVELOPMENT IN CHILDREN AND ADOLESCENTS WITH HEMATOLOGICAL MALIGNANCIES WITHIN THE EMA
C.M. Zwaan, MD, PhD, Netherlands

Ruxolitinib Significantly Enhances in vitro Apoptosis in Hodgkin Lymphoma (HL) and Primary Mediastinal B-Cell Lymphoma (PMBL) and Survival in a Lymphoma Xenograft Murine Mouse: an AYA Therapeutic Opportunity
Selena R. Levine1, Tishi Shah1, Jessica Hochberg1, Janet Ayello1, Erin Morris1, Carmella van de Ven1 and Mitchell S. Cairo1,2,3,4,5
Ibrutinib Significantly Inhibited Bruton’s Tyrosine Kinase (BTK) Phosphorylation, In Vitro Proliferation and Enhanced Overall Survival in a Preclinical Burkitt Lymphoma (BL) Model

Gaurav Nayyar1*, Yaya Chu1*, Tishi Shah1, Matthew Barth3, Rodney R. Miles4, Janet Ayello3, Erin Morris3, Lauren Harrison1, Carmella van de Ven1, Paul Galardy5, Stanton C. Goldman6, Megan S. Lim7, Michelle Hermiston8, Linda M. McAllister-Lucas9, Lisa Giulino-Roth10, Sherrie L. Perkins4, and Mitchell S. Cairo1,11,12,13

1Department of Pediatrics, 2Cell Biology & Anatomy, 11Microbiology & Immunology, 12Medicine, 13Pathology, New York Medical College, Valhalla, NY, Valhalla, 3Pediatrics, University of Buffalo, Buffalo, NY, 4Pathology, University of Utah, Salt Lake City, UT, 5Pediatrics, Mayo Clinic, Rochester, MN, 6Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX, 7Pathology and Laboratory Medicine, University of Pennsylvania, PA, 8Pediatrics, University of California, San Francisco, CA, 9Pediatrics, University of Pittsburgh, Pittsburgh, PA, 10Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY. *Authors contributed equally to this work.

Omipalisib (GSK458), a Dual Pan-PI3K/mTOR Inhibitor, Exhibits in vitro and in vivo Activity in Chemotherapy-Sensitive and –Resistant Models of Burkitt Lymphoma

Thomas Ippolito1, Greg Tang1, Cory Mavis2, Juan Gu2, Francisco Hernandez-Illizaliturri2, Matthew J. Barth1

1Department of Pediatrics, University at Buffalo, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; 2Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Can FDG-PET Replace Biopsy for the Evaluation of Residual Tumor in Mature B Cell NHL?

Hany Abdel Rahman, MD1, Samah Semary, MD2, Gehad Taha, MD3, Naglaa El Kenaai MD4, Iman Zaki MD5, Walid Omar MD6, Nouran Yasser MSc7, Ola Ahmed MSc7

1Department of pediatric oncology National Cancer Institute Cairo University and Children Cancer Hospital, 2Department of Pediatric Oncology, Faculty of Medicine Beni Sweif University and Children Cancer Hospital, 3Department of Surgery, Helwan University and Children Cancer Hospital, 4Department of Pathology, National Cancer Institute Cairo University and Children Cancer Hospital, 5Department of Radio-diagnosis National Cancer Institute Cairo University, and Children Cancer Hospital, 6Department of
Application of the International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLLSS) to Pediatric Patients Newly Diagnosed with B-Cell Non-Hodgkin’s Lymphoma (B-NHL) Enrolled in the AIEOP LNH-97 Protocol

Daniela Onofrillo, Silvia Pascale, Elisa Carraro, Davide Massano, Lara Mussolin, Rosamaria Mura, Luciana Vinti, Salvatore Buffardi, Piero Farruggia, Simone Cesaro, Alessandra Tolva, Patrizia Bertolini, Matilde Piglione, Annalisa Tondo, Nicola Santoro, Alberto Garaventa, Luca Lo Nigro, Alessandra Sala, Marta Pillon

1Pediatric Hemato-Oncology Unit, Hematology Dpt, Hospital of Pescara, 2Clinic of Pediatric Hemato-Oncology, Hospital-University of Padova, Padova, 3Istituto di Ricerca Pediatrica, Fondazione Città della Speranza, Padova, 4Pediatric Hematology-Oncology, Ospedale Pediatrico Microcitemico, Cagliari, 5Pediatric Hemato-Oncology Dpt, IRCCS, Bambino-Gesù Children’s Hospital, Roma, 6Pediatric Hemato-Oncology Unit, Pausilipon Hospital, Napoli, 7Department of Paediatric Haematology-Oncology, IRCCS, Azienda Ospedaliera Universitaria di Parma, Parma, 8Pediatric Hematology-Oncology Unit, G.B. Rossi Hospital, Verona, 9Pediatric Hematology / Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, 10Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria di Parma, Parma, 11Hematology-Oncology Unit, Regina Margherita Hospital, University of Torino, Torino, 12Pediatric Hemato-Oncology Dpt, Meyer University-Hospital, Firenze, 13Division of Pediatric Hematology Oncology, Department of Pediatrics, Bari, 14Hemato-Oncology Unit, Gaslini Children’s Hospital, Genova, 15Center of Paediatric Haematology, Azienda Policlinico-OVE, Catania, 16Department of Paediatrics, Ospedale San Gerardo, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy

Whole-body MRI with Diffusion Weighted Imaging with Body Suppression (DWIBS) in the Follow up of Pediatric Non-Hodgkin Lymphoma: a Comparison with 18F-FDG PET-CT


1Department of Hematology and Oncology, Anna Meyer Children's University Hospital, Florence, 2Nuclear Medicine Unit, Careggi University Hospital, Florence, 3Pediatric Radiology, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy

A Genomic Classification Model Enables Risk Stratification of Paediatric Endemic Burkitt Lymphoma


1Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle upon Tyne, UK, 2College of Medicine, Queen Elizabeth Central Hospital Department of Paediatrics, Blantyre, Malawi, 3West Middlesex University Hospital, Department of Histopathology, Isleworth, UK, 4Imperial College London, Department of Histopathology, London, UK, 5Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, 6Department of Nuclear Medicine National Cancer Institute Cairo University and Children Cancer Hospital, 7Department of Clinical Research, Children Cancer Hospital, Egypt.
Change to OEPA/COPAC and PET-CT Based Treatment Strategy from Former ABVD/COPP for Treating Pediatric Hodgkin's Lymphoma - Lessons Learnt from Chandigarh, India

Jaikumar Ramamoorthy, Deepak Bansal, Sonali Mohapatra, Amita Trehan
Pediatric Hematology Oncology Unit, Department of Pediatrics, Advanced Pediatric Centre, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Biology of Anaplastic Large Cell Lymphoma –
Discussant: Megan Lim, MD, PhD, USA

Investigating the Functional Impact of Single Nucleotide Variants in Anaplastic Large Cell Lymphoma
Hugo Larose¹, Shahid Mian², Edem Nuglozeh², Feroze M.S. Fazaludeen³, Ahmed Elmouna², Ibraheem Ashankyty², Ming-Qing Du¹, Gerald Hoefler⁴, Sarka Pospisilova⁵, Wilhelm Woessmann⁶, Christine Damm-Welk⁷, Alina Fedorova⁷, Laurence Lamant⁸, Michaela Schlederer⁹, Olaf Merkel⁹, Lukas Kenner⁹,¹⁰,¹¹ and Suzanne D. Turner¹
¹Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK CB20QQ, ²Molecular Diagnostics and Personalised Therapeutics Unit, Colleges of Medicine and Applied Medical Sciences, University of Ha’il, Ha’il, Saudi Arabia, ³Department of Neurobiology, University of Eastern Finland, Finland, ⁴Medical University of Graz, Graz, Austria, ⁵CEITEC, Brno, Czech Republic, ⁶Justus-Liebig University, Giessen, Germany, ⁷Belarusian Centre for Paediatric Oncology, Haematology and Immunology, Minsk, Belarus, ⁸Institut Universitaire du Cancer Toulouse, Oncopole et Université Paul-Sabatier, Toulouse, France, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰University of Veterinary Medicine Vienna, Vienna, Austria, ¹¹Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria

Quantification of Minimal Disseminated Disease in Npm-ALK-Positive Anaplastic Large Cell Lymphoma: Validation Cohort and Method
C. Damm-Welk¹, M. Zimmermann¹, A. Attarbaschi², N. Kutscher¹, J. Schieferstein¹, I. Oschlies³, W. Klapper³, W. Woessmann¹
¹NHL-BFM study center, Dept. of Pediatric Hematology and Oncology, Giessen, Germany, ²Dept. of Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Medical University of Vienna, ³Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel, Germany

NPM-ALK Expression Levels are Associated to Different miRNA Profiles in Paediatric Anaplastic Large Cell Lymphoma
Anna Garbin¹,² Federica Lovisa¹,² Katia Basso³, Antony B. Holmes³, Elisa Carraro¹, Marco Pizzi⁴, Alberto Garaventa⁵, Annalisa Tondo⁶, Rossella Mura⁷, Salvatore Buffardi⁸, Giuseppe Basso¹,² Emanuele S.G. D’Amore⁹, Marta Pillon¹, Lara Mussolin¹,²
The AP-1 – BATF and –BATF3 Module: Divergent Roles in Tumour Growth, Invasion and Angiogenesis in Anaplastic Large Cell Lymphoma

Liang Huan-Chang\textsuperscript{1,7}, Prutsch N\textsuperscript{1}, Gurnhofer E\textsuperscript{1}, Timelthaler G\textsuperscript{2}, Eferl R\textsuperscript{2}, Tangermann S\textsuperscript{3}, Horvath J\textsuperscript{4}, Stoiber D\textsuperscript{4,5}, Mathas S\textsuperscript{6,7}, Kenner L\textsuperscript{1,3,4}, Merkel O\textsuperscript{1,7}*

\textsuperscript{1}Clinical Institute for Pathology, Medical University of Vienna, Vienna, Austria; \textsuperscript{2}Institute of Cancer Research, Medical University of Vienna, Vienna, Austria; \textsuperscript{3}Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; \textsuperscript{4}Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria; \textsuperscript{5}Institute of Pharmacology, Medical University of Vienna, Vienna, Austria; \textsuperscript{6}Hematology, Oncology and Tumour Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany; \textsuperscript{7}European Research Initiative on ALK-related malignancies (ERIA), Cambridge, UK. * Correspondence: olaf.merkel@meduniwien.ac.at

Large B-Cell Lymphomas with ALK-Rearrangement Display a Different Genetic and Epigenetic Profile than Diffuse Large B-Cell Lymphoma

Wagener Rabea\textsuperscript{1,#}, Schnaudt C\textsuperscript{1,#}, Kleinheinz K\textsuperscript{2,3}, Ammerpohl O\textsuperscript{1}, Altmüller J\textsuperscript{4}, Thiele H\textsuperscript{5}, Kolarova J\textsuperscript{1}, Agirre X\textsuperscript{6}, Nürnberg P\textsuperscript{4}, Brousset P\textsuperscript{7,8}, Klapper W\textsuperscript{9}, Laurent C\textsuperscript{7}, Martin-Subero I\textsuperscript{10}, Prósper F\textsuperscript{6}, Woessmann W\textsuperscript{11}, Xerri L\textsuperscript{12}, Schlesner M\textsuperscript{2,13}, Siebert R\textsuperscript{1}

\textsuperscript{1}Institute of Human Genetics, University Ulm and Ulm University Medical Center, Ulm, Germany, \textsuperscript{2}German Cancer Research Center DKFZ, Division of Theoretical Bioinformatics, Heidelberg, Germany, \textsuperscript{3}Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg, Germany, \textsuperscript{4}Cologne Center for Genomics, Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany, \textsuperscript{5}Cologne Center for Genomics, University of Cologne, Cologne, Germany, \textsuperscript{6}Area de Oncología, Centro de Investigación Médica Aplicada, Ciberonc, Universidad de Navarra, Pamplona, Spain, \textsuperscript{7}Department of Pathology, Institut Universitaire du Cancer Toulouse Oncoface, CHU de Toulouse, Toulouse, France, \textsuperscript{8}Laboratoire d'excellence Labex TOUCAN, Toulouse, France, \textsuperscript{9}Hematopathology Section, Christian-Albrechts-University, Kiel, Germany, \textsuperscript{10}Institut D'investigaciones Biomedicas August Pi i Sunyer, Center for Biomedical Diagnosis, Barcelona, Spain, \textsuperscript{11}Pediatric Hematology and Oncology, Justus-Liebig-University, Gießen, Germany, \textsuperscript{12}Department of Bio-Pathology, Institut Paoli-Calmettes and Aix-Marseille Univ, Marseille, France, \textsuperscript{13}German Cancer Research Center DKFZ, Bioinformatics and Omics Data Analytics, Heidelberg, Germany. # shared first-authorship
Therapy and Outcome of Children and Adolescents with Progressive or Relapsed Lymphoblastic Lymphoma: Updated NHL-BFM Experience

Stephanie Müller¹, Heidrun Herbrüggen¹, Andishe Attarbaschi², Edita Kabickova³, Felix Niggli⁴, Iliske Oschlies⁵, Wolfram Klapper⁶, Martin Zimmermann⁶, Wilhelm Woessmann⁷, Birgit Burkhardt¹
¹Pediatric Hematology and Oncology, University Hospital Muenster, Germany; ²Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Vienna, Austria; ³Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic; ⁴Pediatric Hematology and Oncology, University Hospital, Zürich, Switzerland, ⁵Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany; ⁶Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany; ⁷Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany

Beneficial Effect of aGVHD on Outcomes After Allogeneic Stem Cell Transplantation for Refractory LBL in Children

Tetsuo Mitsui¹, Naoto Fujita², Yuhki Koga³, Reiji Fukano⁴, Tomoo Osumi⁵, Makiko Mori⁶, Koji Kato⁷, Katsuaki Koh⁸, Yuri Okimoto⁹, Masami Inoue⁶, Yoshiko Hashii¹⁰, Atsushi Sato¹¹, Yoshiko Atsuta¹², Junji Suzumiya¹³, Ryoji Kobayashi¹⁴
¹Department of Pediatrics, Yamagata University Hospital, Yamagata, Japan; ²Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan; ³Department of Pediatric Medicine for Hospital Collaboration, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; ⁴Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan; ⁵Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan; ⁶Department of Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan; ⁷Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; ⁸Department of Hematology and Oncology, Chiba Children's Hospital, Chiba, Japan; ⁹Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan; ¹⁰Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan; ¹¹Department of Hematology/Oncology, Miyagi Children’s Hospital, Sendai, Japan; ¹²Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; ¹³Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital Cancer Center, Izumo, Japan; ¹⁴Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan

BEAM-Campath Conditioning Prior to Allogeneic Stem Cell Transplantation in First Remission in Two Cases of Hepatosplenic T Cell Lymphoma

Lane, Jonathan P.¹, Lau, M.², Barge, D.³, Shenton, G.¹, Skinner, R.¹, James, B.², Wilkins, S.², Bomken, S.¹,⁴
¹Paediatric Oncology and Haematology, Great North Children’s Hospital, Newcastle upon Tyne, UK; ²Children’s and Adolescent Oncology and Haematology, Leeds General Infirmary, Leeds, UK; ³Department of Blood Sciences, Royal Victoria Infirmary, Newcastle upon Tyne, UK; ⁴Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
Dissecting EBV-Specific T-cell Responses after Allogeneic EBV-Specific T-Cell Transfer for CNS PTLD

Britta Maecker-Kolhoff¹,², Rebecca E. Schultze-Florey¹,², Sabine Tischer²,³, Leonie Kuhlmann⁴, Patrick Hundsdorfer⁵, Arend Koch⁶, Sarina Ravens⁴, Lilia Goudeva³, Christian Schultze-Florey⁴,⁷, Christian Koenecke⁴,⁷, Rainer Blasczyk³, Ulrike Koehl²,⁸, Hans-Gert Heuft³, Immo Prinz⁴, Britta Eiz-Vesper²,³

¹Pediatric Hematology and Oncology, Hannover Medical School, Hannover,
²Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Hannover,
³Institute for Transfusion Medicine, Hannover Medical School, Hannover,
⁴Institute of Immunology, Hannover Medical School, Hannover,
⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Berlin Institute of Health, Department of Pediatric Hematology and Oncology,
⁶Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Hannover Medical School, Hannover,
⁷Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany

2B8T2M, a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of anti-CD20 Antibody Significantly Enhanced Expanded Natural Killer Cells Cytotoxicity against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD¹, Nang Kham Su, BS¹, Emily K. Jeng², Sarah Alter, PhD³, Peter R. Rhode, PhD³, Gaurav Nayyar¹, Mathew Barth, MD⁴, Dean A. Lee, MD/PhD⁵, Hing C. Wong, PhD², Mitchell S. Cairo MD¹,⁶,⁷,⁸,⁹,¹⁰

¹Pediatrics, New York Medical College, Valhalla, NY,
²HCW Biologics, Miramar, FL,
³Altor BioScience, Miramar, FL,
⁴Department of Pediatrics, State University of New York at Buffalo, Buffalo, NY, USA,
⁵Hem/Onc/BMT, Nationwide Children’s Hospital, Columbus OH,
⁶Medicine,
⁷Medicine,
⁸Pathology,
⁹Microbiology and Immunology and
¹⁰Cell Biology and Anatomy, Maria Fareri Children’s Hospital, New York Medical College, Valhalla, NY

Novel Therapeutics in CAYA B-NHL – Discussant:

Michael Link, MD, USA

Low Level of Cerebrospinal fluid (CSF) Rituximab (RTX) following Intravenous Rituximab in Children, Adolescents and Young Adults (CAYA) with de novo Mature B-cell Non-Hodgkin Lymphoma (B-NHL)

Matthew J. Barth¹, Yaya Chu²*, Stanton C. Goldman³, Jessica Hochberg², Javier Oesterheld⁴, Kenneth Heym⁵, Lauren Harrison², Harshini Mahanti², Allyson Flowers², Jackie Basso² and Mitchell S. Cairo²,⁶,⁷,⁸,⁹.

¹Roswell Park Cancer Institute, Buffalo, NY; ³Department of Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX and Texas Oncology, PA; ²Department of Pediatric Hematology/Oncology, New York Medical College, Valhalla, NY; ⁴Levine Children’s Hospital, Charlotte, NC; ⁵Cook Children’s Medical Center, Texas, ⁶Medicine, ⁷Pathology, ⁸Microbiology and Immunology and ⁹Cell Biology and Anatomy, Maria Fareri Children’s Hospital, New York Medical College, Valhalla, NY  *co-primary first authors
Synergistically Enhanced in-vitro Cytotoxicity and Overall Survival in NSG xenografts against Burkitt Lymphoma (BL) and Primary Mediastinal Large B cell Lymphoma (PMBL) by Polatuzumab Vedotin (hu-anti-CD79b-vc-MMAE, PV) alone or in combination with Obinutuzumab

Aradhana Awasthi, MPH, PhD, Dina Edani, MS, Janet Ayello, MS, MT (ASCP), Christian Klein, PhD, and Mitchell S. Cairo, MD

Department of Pediatrics, Medicine, Pathology, Microbiology & Immunology, Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA, Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Switzerland

Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Matthew J. Barth*, Jessica Hochberg*, Lauren Harrison, Stanton Goldman, Allyson Flowers, Mitchell S. Cairo

Pediatric Hematology/Oncology, Roswell Park Comprehensive Cancer Center and University at Buffalo, Buffalo, NY; Pediatric Hematology/Oncology, New York Medical College, Valhalla, NY; Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX; Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology and Anatomy, New York Medical College, Valhalla, NY * Co-first authors

Comparing Survival Rates Between Pediatric and Adult Regimens of Treatment for B-Cell Non-Hodgkin Lymphoma in Adolescents and Young Adults

Rios Ligia, Castro D., Vasquez L., Geronimo J.

Pediatric Oncology Unit, Hospital Edgardo Rebagliati Martins, Medical Oncology Service, Hospital Edgardo Rebagliati Martins, Lima Peru.

Outcomes of Burkitt Lymphomas in Children with a Risk-Stratified Approach at a Tertiary Cancer Center in India

Gaurav Narula*, Anand KC, Maya Prasad, Sneha Shah, Shripad D Banavali

Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India

Biology of CAYA Non-Hodgkin Lymphoma – Discussant: Wolfram Klapper, MD, Germany

Molecular Profiling of Adolescent Hepatosplenic T-cell Lymphoma Reveals Somatic Mutations in EZH2, KRAS, and STAG2

Troy A. McEachron, Leonard S. Sender, Keri B. Zabokrtsky, Aaron F. Sassoon, David W. Craig, John D. Carpten, Van T. Huynh, Zarko Manojlovic, Ivan I. Kirov

Keck School of Medicine, University of Southern California, Los Angeles, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, Children’s Hospital of Orange County, Orange, NantKwest, Culver City, University of California Irvine, Orange, California, United States of America
Peripheral T Cell Lymphoma in Children with Nijmegen Breakage Syndrome (NBS)
Report of 4 Cases
Bozenna Dembowska-Baginska¹, A.Wakulinska¹, M.Stypinska¹, W.Grajkowska², K.Chrzanowska³
Department of Oncology¹, Department of Pathology², Department of Genetics³, The Children’s Memorial Health Institute, Warsaw, Poland

Recurrently Mutated Pathway-Derived Network in Pediatric-Type Follicular Lymphoma
Federica Lovisa¹,², Andrea Binatti³, Alessandro Coppe³, Simona Primerano¹,², Elisa Carraro¹, Marta Pillon¹, Marco Pizzi⁴, Salvatore Buffardi⁵, Fulvio Porta⁶, Piero Faruggia⁷, Raffaela De Santis⁸, Giuseppe Basso¹,², Emanuele SG D’Amore⁹, Stefania Bortoluzzi³ & Lara Mussolin¹,²
¹Clinic of Pediatric Onco-Hematology, Department of Women’s and Children’s Health, University of Padova, ²Istituto di Ricerca Pediatrica Città della Speranza, Padova, ³Department of Molecular Medicine, University of Padova, Padova, ⁴Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padova, ⁵Santobono-Pausilipon Hospital, Napoli, ⁶Children’s Hospital, Spedali Civili, Brescia, ⁷A.R.N.A.S. Ospedali Civico Di Cristina e Benfratelli, Palermo, ⁸IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, ⁹Department of Pathological Anatomy, San Bortolo Hospital, Vicenza, Italy

Investigation of FOXO1 Mutations in Paediatric Endemic and Sporadic Burkitt Lymphoma
Peixun Zhou¹, Alexander M Newman¹, Filbert Adlar¹, Casey Broadbent¹, Alex E Blain¹, Amber Whitehead¹, Amy Hall¹, George Chagaluka², Elizabeth Molyneux², Simon Bailey¹, Chris M Bacon¹,³, Simon Bomken¹,⁴, Vikki Rand¹
¹Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle upon Tyne, UK, ²College of Medicine, Queen Elizabeth Central Hospital Department of Paediatrics, Blantyre, Malawi, ³Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, ⁴Department of Paediatric and Adolescent Haematology and Oncology, The Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Targeted Panel for Pediatric T-LBL
Charlotte Rüther¹, Tasneem Khanam¹, Christoph Bartenhagen², Jochen Seggewiś³, Heidi Herbrüggen¹, Stephanie Müller¹, Christian Wünsch⁴, Ilske Oschlies⁵, Wolfram Klapper⁵, Martin Dugas⁴, Sarah Sandmann⁴, Birgit Burkhardt¹
¹Pediatric Hematology and Oncology, University Hospital Muenster, ²Department of Experimental Pediatric Oncology, University Hospital Cologne, ³Institute of Human Genetics, Muenster University, ⁴Institute of Medical Informatics, Muenster University, ⁵Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany
Retrospective analysis of clinical features and treatment outcomes of children with Hodgkin’s Lymphoma treated with different chemotherapy protocols at tertiary care centre in Pakistan.

Mahreen A, Wali RM, Sindhu II, Riaz S

Department of Pediatric Oncology, Shaukat Khanum Cancer Hospital and Research Center Lahore, Pakistan; Department of Nuclear Medicine. Shaukat Khanum Cancer Hospital and Research Center Lahore, Pakistan

Clinical Features and Outcomes of Pediatric Hodgkin Lymphoma in Asia

Michi Kamei, Yuhki Koga, Shih-Hsiang Chen, Chao-Ping Yang, Allen Eng Juh Yeoh, Hany Ariffin, Reiji Fukano, Masahiro Sekimizu, Shosuke Sunami, Junichi Ueyama, Tetsuo Mitsui, Takeshi Mori, Tomoo Osumi, Kentaro Ohki, Fumiko Tanaka, Naoto Fujita, Tetsuya Mori, Ryoji Kobayashi

Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Japan, Department of Pediatrics, Graduate School of Medical Sciences Kyushu University, Japan, Division of Hematology/Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Taiwan, National University Cancer Institute Singapore, Singapore, Department of Paediatrics University of Malaya Medical Centre, Malaysia, Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Japan, Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Japan, Department of Pediatrics, Japanese Red Cross Narita Hospital, Japan, Department of Pediatrics, Tottori University Hospital, Japan, Department of Pediatrics, Yamagata University Hospital, Japan, Children's Cancer Center, National Center for Child Health and Development, Japan, Children's Cancer Center, National Center for Child Health and Development, Japan, Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Japan, Department of Pediatrics, Saiseikai Yokohamashi Nanbu Hospital, Japan, Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Japan, Department of Pediatrics, St. Marianna University School of Medicine Hospital, Japan, Department of Pediatrics and Adolescence, Sapporo Hokuyu Hospital, Japan

The Clinical Features and Therapeutic Effect for the Treatment of T cell Lymphoblastic Lymphoma / Leukemia in Childhood and Adolescence: Results of a Single Center in China

Ling Jin, Yonghong Zhang, Jing Yang, Yanlong Duan, Shuang Huang, Meng Zhang, Chunju Zhou, Zifen Gao, Xiaoge Zhou

Hematology Oncology Center, Beijing Children’ Hospital, Capital Medical University, Beijing, Pathology, Medical School of Beijing University, Beijing, Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Protocol B-NHL-BFM 95+-/ Rituximab: 10-year Experience

T.Valiev, G.Mentkevich

Pediatric Oncology and Hematology Research Institute of N.N.Blokhin National Cancer Center of the Ministry of Health of Russian Federation, Moscow, Russia
Children are 6 times More Likely than Adults to Develop Post-Transplant Lymphoproliferative Disease (PTLD)  

\[ \text{James Ford, DO,} \quad \text{Jennifer Sanmann, PhD,} \quad \text{Kelly Erickson, MPH,} \quad \text{Martin Bast,} \quad \text{Wendy Grant, MD,} \quad \text{Valerie Shostrom, MS,} \quad \text{Alan Langnas, DO,} \quad \text{Timothy Greiner, MD,} \quad \text{Peter Coccia, MD.} \]

\[ \text{University of Nebraska Medical Center, Omaha, Nebraska, 2Children’s Hospital and Medical Center of Omaha, Omaha, Nebraska, USA} \]

**Saturday, September 29, 2018**

7:00 AM – 1:00 PM  
**REGISTRATION**

7:30 – 8:15 AM  
**MEET THE PROFESSORS (CHOOSE ONE SESSION)**

**Session 1**  
**MINIMAL DISSEMINATED DISEASE (MDD) AND MINIMAL RESIDUAL DISEASE (MRD) IN CHILDHOOD AND ADOLESCENT NHL**

Bruce Shiramizu, MD, USA

**Session 2**  
**DIAGNOSIS AND TREATMENT OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE: CHALLENGING CASES**

Thomas Gross, MD, PhD, USA

**Session 3**  
**DIAGNOSIS AND MANAGEMENT OF LYMPHOBLASTIC LYMPHOMA: CHALLENGING CASES**

Birgit Burkhardt, MD, PhD, Germany

**Session 4**  
**DIAGNOSIS AND MANAGEMENT OF ALCL: CHALLENGING CASES**

Laurence Brugieres, MD, France

**Session 5**  
**DIAGNOSIS AND MANAGEMENT OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA: CHALLENGING CASES**

Lisa Giulino-Roth, MD, USA

8:30 – 10:00 AM  
**PLENARY SESSION IX - BEST ORAL ABSTRACTS IN CHILDHOOD, ADOLESCENT AND YOUNG ADULT NON-HODGKIN LYMPHOMA**

Moderators - Mitchell S. Cairo, MD, USA, & Auke Beishuizen, MD, PhD, Netherlands

8:30 – 8:45 AM  
**Regulation of Cytokine Release and anti-Tumor Effect of anti-CD20 CAR Modified Expanded Natural Killer Cells by ALT-803, an IL-15 Superagonist**

Yaya Chu, PhD\(^1\), Nang Kham Su, BS\(^1\), Carl Hamby, PhD\(^2\), Emily K. Jeng\(^3\), Sarah Alter, PhD\(^4\), Mathew Barth, MD\(^5\), Hing C. Wong, PhD\(^3\), Dean A. Lee, MD/PhD\(^5\), Mitchell S. Cairo MD\(^1,7,8,9,10,11\)

\[ ^1 \text{Pediatrics, New York Medical College, Valhalla, NY,} ^2 \text{Microbiology and Immunology, New York Medical College, Valhalla, NY, USA,} ^3 \text{HCW Biologics, Miramar, FL,} ^4 \text{Altor BioScience, Miramar, FL,} ^5 \text{Department of Pediatrics, State University of New York at Buffalo, Buffalo, NY, USA,} ^6 \text{Hem/Onc/BMT, Nationwide Children’s Hospital, Columbus} \]
8:45 – 9:00 AM  
**IG-MYC-Rearranged Neoplasms with Precursor B-Cell Immunophenotype in Pediatric and Adolescent Patients**  
Heidi Herbrueggen¹, Jonas Rohde², Anja Moericke³, Andishe Attarbaschi⁴, Richard Ratei⁵, Monika Brueggemann⁶, Reiner Siebert⁷, Brigitte Schlegelberger⁸, Wolfram Klapper⁹, Martin Zimmermann¹⁰, Willi Woessmann¹¹, Birgit Burkhardt¹  
¹Pediatric Hematology and Oncology, University Hospital Muenster, Germany; ²General Pediatrics, University Hospital Muenster, Germany; ³Department of Pediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany; ⁴Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Medical University of Vienna, Vienna, Austria; ⁵Helios Klinikum Bad Saarow, Department of Hematology, Oncology and Palliative Care, Bad Saarow, Germany; ⁶Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; ⁷Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany; ⁸Department of Human Genetics, Hannover Medical School, Hannover, Germany; ⁹Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany; ¹⁰Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany, ¹¹Pediatric Hematology and Oncology, Justus Liebig University, Giessen, Germany

9:00 – 9:15 AM  
**Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma**  
Jessica C. Hochberg, MD ¹, Liana Klejmont, Pharm D ¹, Lauren Harrison, RN, MSN ¹, Allyson M. Flower, MD ³, Qiuhi Shi, PhD ², Jaclyn Basso, RN, MSN, PNP ¹ and Mitchell S. Cairo, MD ³, ¹Pediatrics, New York Medical College, Valhalla, NY; ²Statistics, New York Medical College, Valhalla, NY; ³Medicine, ⁴Pathology, ⁵Microbiology and Immunology, ⁶Cell Biology and Anatomy, New York Medical College, Valhalla, NY

9:15 – 9:30 AM  
**NPM-ALK REGULATES IMMUNE ESCAPE THROUGH CD48 IN ALK+ ALCLS**  
Rui Wu ¹, Elena Ivan ¹, Delphine Rolland ¹, Anagh Sahasrabuddhe ¹, Kojo S. Elenitoba-Johnson ¹, Megan S. Lim ¹, ² ¹Department of Pathology and Laboratory Medicine, University of Pennsylvania, PA; ²Department of Pathology, Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania

9:30 – 9:45 AM  
**Biallelic Inactivation of TP53 is Associated with an Increased Risk of Relapse in Paediatric B-Cell Non-Hodgkin Lymphoma (B-NHL)**  
Alexander M Newman¹, Masood Zaka¹, Peixun Zhou¹, Amy Erhorn¹, Amy Barnard¹, Rachel E Crossland¹, Sarah Wilkinson¹, Amir Enshaei¹, Mary Taj², Katrina Wood³, Despina Televantou³, Suzanne D Turner⁴, Amos Burke⁵, Christine J Harrison¹, Simon Bomken¹,⁶, Chris M Bacon¹,³, Vikki Rand²  
¹Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle upon Tyne, UK, ²Department of Paediatric Oncology, Royal Marsden Hospital, Sutton, Surrey, UK, ³Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, ⁴Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK,
9:45 – 10:00 AM  Interim Positron Emission Tomography And Childhood Hodgkin International Prognostic Score Can Predict Survival Of Children With Hodgkin Lymphoma In Developing Countries
Reham Khedr¹, Sally Mahfouz¹, Hoda Fathy², Lobna Shalaby³
¹Pediatric Oncology Department, ²Nuclear Medicine Department, National Cancer Institute - Cairo University, Children Cancer Hospital, Egypt, 57357

10:00 – 10:15 AM  COFFEE BREAK

10:15 - 11:45 AM  PLENARY SESSION X - LYMPHOBLASTIC LYMPHOMA
Moderators - Birgit Burkhardt, MD, PhD, Germany & Michelle Hermiston, MD, PhD, USA

10:15 – 10:35 AM  PROGNOSTIC GENETIC FACTORS IN CHILDHOOD AND ADOLESCENT T-LYMPHOBLASTIC LYMPHOMA
Birgit Burkhardt, MD, PhD, Germany

10:35 – 10:55 AM  DIAGNOSIS AND TREATMENT OF CHILDHOOD AND ADOLESCENT B-LYMPHOBLASTIC LYMPHOMA
Birte Wistinghausen, MD, USA

10:55 – 11:05 AM  Genomic Analysis of Early T-Cell Precursor Lymphoblastic Lymphoma
Xinjie Xu¹,², Christian N Paxton¹, Robert J. Hayashi³, Sherrie L Perkins¹,², Rodney R. Miles¹,²
¹ARUP Laboratories, Salt Lake City, Utah, ²Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, ³Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, MO, USA

11:05 – 11:15 AM  Glucocorticoids Paradoxically Induce Steroid Resistance Through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Lauren K. Meyer¹, Cristina Delgado-Martin¹, Benjamin J. Huang¹, Anica M. Wandler¹, Terzah M. Horton², David T. Teachey³, Kevin M. Shannon¹*, and Michelle L. Hermiston¹*
¹University of California, San Francisco, CA, ²Baylor College of Medicine, Houston, TX, ³University of Pennsylvania, Philadelphia, PA, USA  *K.M.S. and M.L.H. contributed equally to this study

11:15 – 11:25 AM  Global Genetic Profiling of a Pediatric Series of T-Cell Lymphoblastic Lymphoma
Idoia Martin-Guerrero*, Joan Enric Ramis-Zaldivar*, Verónica Celis, Olga Balagué, Jaime Verdú, Julia Salmerón-Villalobos, Constantino Sábdio, Marta Garrido, Blanca Gonzalez-Farré, Izziar Astigarraga, Mara Andrés, Itziar Salaverria  *These two authors contribute equally to the study
¹Faculty of Science and Technology, UPV/EHU, Leioa, ²Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ³Hospital Sant Joan de Déu, Esplugues de Llobregat, ⁴Hospital Clínic, Barcelona, ⁵Hospital Clínic, Valencia, ⁶Institut d'Investigacions
Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

AWARDS SESSION BEST ORAL ABSTRACT, BEST POSTER DISCUSSION ABSTRACT & BEST POSTER ABSTRACT
Award Committee – Stanton Goldman, MD, USA; Marta Pillon, MD, Italy; John T. Sandlund MD, USA; Ronit Elhasid, MD, Israel; Oussama Abla, MD, Canada; Friederike Meyer-Wentrup, MD, Netherlands

CLOSING REMARKS
Mitchell S. Cairo, MD, Chair, USA
ABSTRACT SUBMISSION—DEADLINE May 7, 2018 by 5pm EST

a. ABSTRACTS MUST BE RECEIVED BY Monday, May 7, 2018, 5:00 PM EST, TO BE CONSIDERED FOR PRESENTATION.

b. ABSTRACTS MUST ADDRESS SCIENTIFIC QUESTIONS PERTAINING TO CHILDHOOD, ADOLESCENT, OR YOUNG ADULT NON-HODGKIN LYMPHOMA or HODGKIN LYMPHOMA

c. ABSTRACTS WILL BE PUBLISHED IN BRITISH JOURNAL OF HAEMATOLOGY

d. ABSTRACTS ARE TO BE SUBMITTED VIA E-MAIL AS A MICROSOFT WORD DOCUMENT ATTACHMENT TO NHL_SYMPOSIUM@NYMC.EDU.

e. TO PRESENT AN ABSTRACT, APPLICANT MUST BE REGISTERED TO ATTEND THE SYMPOSIUM

f. THERE IS NO ABSTRACT SUBMISSION FEE

g. YOU CAN REGISTER FOR THE SYMPOSIUM AT THE SAME TIME OF ABSTRACT SUBMISSION AT OUR WEBSITE (http://cayanhl.pcrf-kids.org)

FINANCIAL NEED AWARDS

a. FINANCIAL NEED AWARD --REGISTRANTS FROM A LOW-RESOURCED COUNTRY WHO HAVE AN ABSTRACT ACCEPTED MAY APPLY FOR A MERIT AWARD (REGISTRATION FEE WAIVER). A LETTER BY E-MAIL DETAILING REASONS FOR FINANCIAL NEED MUST BE ATTACHED WITH THE ABSTRACT SUBMISSION. (LIMIT--10 FINANCIAL NEED AWARDS).

BEST ABSTRACT AWARDS

a. BEST ORAL ABSTRACTS WILL BE SELECTED BY SCIENTIFIC MERIT FOR ORAL PRESENTATION IN EACH PLENARY SESSION OF THE MEETING. AN AWARD OF $1000 (US) WILL BE MADE FOR THE BEST ORAL PRESENTATION AT THE MEETING.

b. EIGHTEEN ABSTRACTS OF NOTEWORTHY SCIENTIFIC MERIT WILL BE SELECTED FOR A POSTER DISCUSSION SESSION AT THE MEETING. AN AWARD OF $1000 (US) WILL BE MADE FOR THE BEST POSTER DISCUSSION PRESENTATION AT THE MEETING.

c. ADDITIONALLY, OTHER ACCEPTED ABSTRACTS WILL BE PRESENTED IN THE GENERAL POSTER SESSION. AN AWARD OF $1000 (US) WILL BE MADE FOR THE BEST POSTER IN THE GENERAL SESSION AT THE MEETING.

ABSTRACT FORMAT

a. ABSTRACTS MUST BE SUBMITTED VIA E-MAIL AS A MICROSOFT WORD DOCUMENT ATTACHMENT; ABSTRACT SHOULD NOT EXCEED 400 WORDS INCLUDING TITLE AND BODY (AUTHORS' NAMES AND INSTITUTIONS ARE NOT COUNTED). (Limit to one figure or one table are also not counted).

b. USE 10 PT. TIMES FONT.

c. ABSTRACT FORMAT IS AS FOLLOWS:

TITLE (TITLE CASE)
AUTHORS, INSTITUTION, CITY, STATE OR PROVINCE, COUNTRY
BODY (USE THE FOLLOWING HEADINGS):
BACKGROUND
OBJECTIVES
DESIGN/METHODS
RESULTS
CONCLUSION

THE FOLLOWING INFORMATION MUST BE INCLUDED IN THE E-MAIL WITH EACH SUBMISSION:

a. NAME OF CORRESPONDING AUTHOR
b. DEPARTMENT/INSTITUTION, CITY, COUNTRY
c. TELEPHONE NUMBER
d. E-MAIL ADDRESS OF CORRESPONDING AUTHOR
e. CATEGORY DESIRED (AUTHORS MUST INDICATE THE ONE SCIENTIFIC CATEGORY)

<table>
<thead>
<tr>
<th>1. B-CELL NON-HODGKIN LYMPHOMA</th>
<th>7. NOVEL THERAPEUTICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. AYA NON-HODGKIN AND HODGKIN LYMPHOMA</td>
<td>8. LYMPHOBLASTIC LYMPHOMA</td>
</tr>
<tr>
<td>3. T AND NK NON-HODGKIN LYMPHOMA</td>
<td>9. RELAPSED/REFRACTORY NHL</td>
</tr>
<tr>
<td>4. LYMPHOMA IMMUNOLOGY, BMT &amp; CELL THERAPY</td>
<td>10. LATE EFFECTS / SURVIVORSHIP OF NHL</td>
</tr>
<tr>
<td>5. ANAPLASTIC LARGE CELL LYMPHOMA</td>
<td>11. HODGKIN LYMPHOMA</td>
</tr>
<tr>
<td>6. LYMPHOMA TRANSLATIONAL BIOLOGY</td>
<td>12. NHL IN LOW RESOURCED COUNTRIES</td>
</tr>
</tbody>
</table>

• ABSTRACTS PERTINENT TO CHILDHOOD, ADOLESCENT AND YOUNG ADULT NON-HODGKIN AND HODGKIN LYMPHOMA THAT HAVE BEEN ACCEPTED/PRESENTED AT SCIENTIFIC MEETINGS WITHIN THE PAST 18 MONTHS ARE ALSO ACCEPTABLE FOR SUBMISSION TO THIS SYMPOSIUM.

• QUESTIONS SHOULD BE ADDRESSED TO MIGUEL MUNIZ AT NHL_SYMPOSIUM@NYMC.EDU

• SUBMIT ABSTRACT BY E-MAIL TO: NHL_SYMPOSIUM@NYMC.EDU

• ABSTRACT REVIEW:

a. ABSTRACTS WILL BE PEER-REVIEWED ACCORDING TO SCIENTIFIC CATEGORIES.

b. NOTIFICATION OF ACCEPTANCE OR REJECTION OF ABSTRACTS WILL BE MADE VIA E-MAIL ON OR AROUND June 11th, 2018.

c. THE DECISION OF THE REVIEWING COMMITTEES REGARDING THE ACCEPTANCE OF ABSTRACTS IS FINAL.
CME Information
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of New York Medical College and Pediatric Cancer Research Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

New York Medical College designates this Live activity for a maximum of 24.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LOCATION: ROTTERDAM, THE NETHERLANDS
Rotterdam, a city known for its architecture, is a Dutch city situated in the west part of The Netherlands. A major logistic and economic center, Rotterdam is Europe’s largest port city with a population of 633,000 and over 2.9 million inhabitants in its metropolitan area combined with The Hague. Rotterdam is a modern, thriving cosmopolitan city with a breathtaking skyline and a wealth of cultures and ethnicities.

VENUE: DE DOELEN INTERNATIONAL CONGRESS CENTRE
The Willem Burger Complex
De Doelen ICC is Rotterdam’s central arena for the exchange of information and cultural events. De Doelen ICC is divided into 3 complexes each with its own entrance. De Doelen ICC has earned a national and international reputation for its state of the art venue. The 6th International Symposium is being held in the Willem Burger Complex.

REACHING ROTTERDAM:
Symposium attendees can reach Rotterdam by air and train. Amsterdam’s Schiphol Airport (AMS) is located 37 miles north of Rotterdam. From Schiphol Airport travel to Rotterdam City Center Rail Station is by high speed rail service operated by NS Dutch Railways. The high speed train operates from Schiphol Airport to Rotterdam City Center Rail Station every 15 minutes and the journey takes 27 minutes. De Doelen ICC and recommended hotels are within walking distance from Rotterdam City Center Rail Station.

For travelers arriving from Germany, Italy, France, Spain and the United Kingdom flights are available to Rotterdam The Hague Airport (RTM). Rotterdam The Hague Airport is located 4 miles north of the city with taxi service available.

ACCOMMODATIONS/REGISTRATION:
RESERVE ONLINE at http://cayanhl.pcrf-kids.org
A limited number of favorable hotel rates for conference registrants are available at:
The Bilderberg Park Hotel; Easy Hotel Rotterdam City Centre; The Holiday Express Rotterdam; Marriott Rotterdam
All hotels are within walking distance of De Doelen ICC.

Hotel accommodations must be reserved by August 26, 2018 to assure availability of blocked rooms at conference rates.

NOTE: All recommended hotels are fully accessible for registrants with disabilities. In order to accommodate any special needs please specify when registering for the conference.

CONFERENCE REGISTRATION FEES INFORMATION *USD:

<table>
<thead>
<tr>
<th>Registration</th>
<th>By August 15th, 2018</th>
<th>After August 15th, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians / Scientists</td>
<td>$ 750.00 USD</td>
<td>$ 900.00 USD</td>
</tr>
<tr>
<td>Allied Professional / In Training</td>
<td>$ 450.00 USD</td>
<td>$ 600.00 USD</td>
</tr>
<tr>
<td>Pharmaceutical Representative</td>
<td>$ 1,000.00 USD</td>
<td>$ 1,250.00 USD</td>
</tr>
<tr>
<td>CME Credit</td>
<td>$ 25.00 USD</td>
<td>$ 25.00 USD</td>
</tr>
</tbody>
</table>

US currency only

REGISTER ONLINE: http://cayanhl.pcrf-kids.org

Refund Policy:
50% of registration is refundable by July 15th, 2018, thereafter there are no refunds.

Late and On-Site Registration (After July 15th, 2018):
Attendees who register after July 15th, 2018 will be charged the late/on-site registration fee. On-site registration will begin on local times list below in the first-floor lobby of the De Doelen International Congress Centre.

Meeting Cancellation Policy:
The Pediatric Cancer Research Foundation (PCRF), New York Medical College and Erasmus MC reserve the right to modify or cancel any or all activities associated with this meeting due to unforeseen circumstances. In the event that we have to unexpectedly cancel this meeting before July 15, 2018, 50% off the registration fee will be returned. If the conference is cancelled after July 15, 2018, there will be no refund.